Company Overview
The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. It operates through a network of franchised clinics, offering routine and affordable chiropractic adjustments using a private pay, non-insurance, cash-based model. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Why Investors Should Care
Revenue has grown at a 20.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $54.90M (+5.2% YoY).
- Trailing 12 Months Year-on-year growth — revenue +13.3%, earnings +43.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.33% |
| 1 Year: | 13.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 43.80% |
Stock Price Performance
| 1 Year: | -21.83% |
| 6 Months: | -3.14% |
| 3 Months: | +0.90% |
| 1 Month: | -1.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross2d ago
- RSI (14)49.96 · Neutral
P/E of 99.44 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 99.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JYNT The Joint Corp. R2K | 8.95 | 99.44 | $127.59M | 0.00% | -3.24% | 7.00% | 20.33% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.51M | 1.73M | 1.82M | 2.51M | 3.43M | 4.14M | 4.27M | 4.97M | 5.50M | 5.51M | 6.00M | 6.54M | 8.65M | 8.80M | 9.24M | 10.68M | 11.17M | 12.73M | 13.64M | 12.59M | 15.41M | 17.55M | 20.22M | 20.99M | 22.44M | 24.89M | 26.45M | 28.30M | 29.31M | 29.47M | - | 29.72M | 30.26M | 30.20M | - | - | - | - | - | - |
| Operating Income | -157.39K | -209.16K | -310.82K | -1.92M | -1.85M | -2.05M | -3.48M | -3.19M | -2.62M | -1.71M | -995.53K | -405.53K | -83.78K | -64.24K | -247.04K | 943.67K | 487.60K | 640.38K | 753.35K | 258.58K | 1.71M | 1.97M | 2.03M | 1.34M | -176.43K | -1.33M | 732.32K | -257.89K | -414.64K | -3.82K | 994.64K | -426.60K | -1.78M | -492.82K | 809.72K | -678.53K | -1.14M | 160.91K | 742.41K | 873.67K |
| Net Income | -127.89K | -133.75K | -202.37K | -1.90M | -1.86M | -1.66M | -3.53M | -3.26M | -2.63M | -1.77M | -1.02M | -431.70K | -31.61K | -50.84K | -207.54K | 952.64K | 462.26K | 616.98K | 814.95K | 115.58K | 1.60M | 2.31M | 2.68M | 1.94M | -205.80K | -871.87K | 731.10K | 2.33M | -320.49K | -716.27K | - | 946.98K | -3.60M | -3.17M | - | - | - | - | - | - |
| Diluted EPS | - | - | -0.04 | - | - | - | - | - | - | - | - | - | 0.00 | - | -0.02 | 0.07 | 0.03 | 0.04 | 0.06 | 0.01 | 0.11 | 0.16 | 0.18 | 0.13 | -0.01 | -0.06 | 0.05 | 0.16 | -0.02 | -0.05 | -0.74 | 0.06 | -0.24 | -0.21 | 0.00 | 0.06 | 0.01 | 0.06 | 0.07 | 0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.96M | 7.12M | 13.84M | 20.52M | 24.92M | 36.66M | 48.45M | 58.68M | 80.86M | 101.25M | 117.70M | 52.16M | 54.90M |
| Operating Income | 439.79K | -1.63M | -9.32M | -15.01M | -3.33M | 142.56K | 3.41M | 5.49M | 5.35M | 828.25K | 318.30K | -1.89M | -913.38K |
| Net Income | 155.63K | -3.03M | -8.80M | -15.17M | -3.43M | 146.70K | 3.32M | 13.17M | 6.58M | 626.71K | -9.75M | - | - |
| Diluted EPS | 0.02 | -0.56 | - | - | -0.26 | 0.01 | 0.23 | 0.90 | 0.44 | 0.04 | -0.65 | -0.38 | 0.19 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.77M | 28.47M | 33.36M | 17.05M | 18.44M | 23.43M | 43.71M | 65.88M | - | 93.49M | 87.21M | 83.15M | 60.97M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 17.61M | 44.34M | 74.58M | 52.09M |
| Cash & Equivalents | 3.57M | 3.52M | 20.80M | 16.79M | 3.01M | 4.22M | 8.72M | 8.46M | 20.55M | - | 9.75M | 18.15M | 25.05M | 23.60M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 3.91M | 2.58M | 2.59M | 2.85M |
| Total Liabilities | - | 10.99M | 12.84M | 12.68M | 10.13M | 17.28M | 22.70M | 37.99M | 44.75M | - | 60.90M | 62.44M | 62.48M | 45.89M |
| Current Liabilities | - | 3.59M | 4.18M | 7.49M | 5.86M | 5.38M | 10.27M | 13.57M | 18.46M | - | 23.22M | 33.57M | 49.04M | 32.82M |
| Long Term Debt | - | - | - | 581.85K | 331.50K | 100.00K | - | - | - | 2.00M | 2.00M | 2.00M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 26.06M | 2.86M | 795.03K | 2.01M |
| Total Equity | -1.14M | -1.22M | 15.63M | 20.68M | 6.93M | 1.15M | 727.50K | 5.72M | 21.13M | - | 32.56M | 24.75M | 20.65M | 15.05M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 14.56M | 14.78M | 15.19M | 15.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -10.85M | -74.13K | 5.45M | 7.52M | 11.18M | - | 8.21M | 14.68M | 9.42M | 1.84M |
| Investing Cash Flow | - | - | - | -2.70M | -372.85K | -1.24M | -7.14M | -4.60M | - | -17.90M | -6.19M | -631.55K | 6.27M |
| Financing Cash Flow | - | - | - | -239.85K | 1.42M | 326.30K | -596.96K | 5.60M | - | 328.61K | 174.12K | -2.00M | -9.81M |
| Capital Expenditure | -241.41K | -659.30K | -4.07M | -1.57M | -449.20K | -1.11M | -3.48M | -3.16M | - | -5.90M | -5.00M | -1.19M | -1.50M |
| Free Cash Flow | - | - | - | -12.42M | -523.34K | 4.34M | 4.04M | 8.03M | - | 2.31M | 9.68M | 8.23M | 334.72K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -9.36M | 8.66M | 6.78M | -1.69M |
| Share Buybacks | 240.00K | - | - | 83.39K | 2.65K | 4.81K | 20.18K | 32.07K | 707.73K | 5.80K | 3.83K | 0 | 11.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 7.4% | -22.9% | -67.3% | -73.1% | -13.4% | 0.4% | 7.0% | 9.4% | 6.6% | 0.8% | 0.3% | -3.6% | -1.7% |
| Net Margin % | 2.6% | -42.6% | -63.6% | -73.9% | -13.8% | 0.4% | 6.9% | 22.4% | 8.1% | 0.6% | -8.3% | - | - |
| ROE % | -12.7% | -19.4% | -42.5% | -219.1% | -297.6% | 20.2% | 58.1% | 62.3% | - | 1.9% | -39.4% | - | - |
| ROCE % | 7.1% | -6.7% | -36.0% | -134.1% | -25.5% | 1.1% | 11.3% | 11.6% | - | 1.2% | 0.6% | -5.5% | -3.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bandera Partners LLC | 27.62% | 3.94M | $36.03M |
| 2 | Skylands Capital, LLC | 6.27% | 893.20K | $8.17M |
| 3 | Blackrock Inc. | 5.29% | 754.52K | $6.90M |
| 4 | Vanguard Capital Management LLC | 4.18% | 595.61K | $5.45M |
| 5 | JCP Investment Management, LLC | 4.17% | 593.91K | $5.43M |
| 6 | First Foundation Advisors | 2.37% | 337.85K | $3.09M |
| 7 | Russell Investments Group, Ltd. | 2.26% | 321.86K | $2.94M |
| 8 | Geode Capital Management, LLC | 2.02% | 287.41K | $2.63M |
| 9 | State Street Corporation | 2.00% | 285.61K | $2.61M |
| 10 | Vanguard Portfolio Management LLC | 1.95% | 277.64K | $2.54M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JYNT
Loss-Making The Joint Corp. (NASDAQ:JYNT) Set To Breakeven - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOT25aRnh2YTRicF9OSWtocS1zdm5oNEdIdXlQM1ltWnIxNS1vM1Y3QjloN1FIcF9PNWY5YnI0Z25nMFN3UmdTVEUyb3lOY1F3X3VkcEd6NjZPT1BKdUtEdS1FU0FfTGNoVHpBakxGN2hUTmlhOG5ScnhUWkt1Y0xwbWZqVllreloyRkxuQ1…
Enterprise value to revenue forward of The Joint Corp. – NASDAQ:JYNT - TradingView
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQcGJFWjRYR1FZaXM3MkJpWWVUZGF5cThJSi1pY1duTGhVc0FGTi1abkY1YmxaR1h3OU5DcXFiNVNOenRFYnVhTUlXNFd5RjNQa2Q5ZGhUY1JwSFFIUURKRHBuWXIwUWtCVzJjQ1BlNlotVEdGSERuWHVKMUpKYU1uUzNTT25sSWdhaloyaz…
Joint Corp (JYNT) director receives 5,714 restricted stock award - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQcFBmTEtaUHpmcUgzd1lyVG5INGpQQnVVU2h6eTE3SEpJLVU0ME1iV3ZWYjVOYjRkaEtGSkNJNUdwSjRjQU5RYVFlajBsWkxWYjUyN1VWT3pNNVczb0JpYlk5VXB5aVF5RmZqTC1KZkloYW1rTnVZcmpkYnZPc2FJSEppZWRVekwza2RrSG…
JYNT stock reflects chiropractic chain's expansion ambitions - Ad-hoc-news.de
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdEUwY01QY3pYb0tucTA4aTB5NWk0Q2NEUUt2NDFRaTFIc3RtakpYYUZack9ZUUloTkVsSFkyQTYyVGR6WWdMMjFfemw5bFZsN2tOcFRPcU5jc3ltVWEtbGJBaHJkdUJueUxkVkdwZWs2X1ZrdVNZbHRqeXNBcWppMDJabGMxV25qeEcxS1…
Bullish Joint Insiders Loaded Up On US$761.5k Of Stock - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNRUlzcEl5NzFfRzRNWFJJSDB3RW5PRlVXU0p5YzlOYU1YWXg3X25nMXFaWXcwb3VjaDRTQXFiWGhseE01VlNYOUlGM1lYUDg0d280bGJVZVBKYWd2WVJSQnFmMmxrU1ZtbUlVbkE4SGpHX3hDdjZBR1RNcUxRZDI2a0QtRVh6MjZKb0owcX…
The Joint Corp.(NasdaqCM: JYNT) dropped from Russell 2500 Index - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNZEVISUMxSFVfdjA0NHNCVm5PcncwQVRIWFAxYy0xTmc2ejdjanNNanNuNlo0VEVPbjhiQWxRNC11TFVybkpFSm5sS3hGMVBBUjN4YWFMYXBvYzhhSmFKcmxJSjBNdmRLcWZoOGFVRjFEa0NlMXREY3R5Z3VNS2RwSXBlWGtoZ0hndmQzWU…
JYNT — Frequently Asked Questions
What is the current share price of The Joint Corp. (JYNT)?
As of 2026-07-14 21:23 PDT, The Joint Corp. (JYNT) trades at $8.95 on NasdaqCM. Its 52-week range is $7.67 to $11.70.
What is the market capitalisation of JYNT?
The Joint Corp. (JYNT) has a market capitalisation of $127.59M on NasdaqCM.
What is the P/E ratio of JYNT?
JYNT trades at a trailing price-to-earnings (P/E) ratio of 99.44. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 8.49.
What is the return on equity (ROE) of JYNT?
JYNT has a return on equity (ROE) of 7.00%. Its return on capital employed (ROCE) is -3.24%.
Is JYNT a good stock to buy?
This page provides a data-driven analysis of The Joint Corp. (JYNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.